Biaffin

Newsletter

kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
Recombinant Human VEGF-C Protein, 1mg  

Recombinant Human VEGF-C Protein, 1mg

Recombinant Human VEGF-C /FLT4L Protein (rhVEGF-C) Thr 103 - Arg 227 was produced in human 293 cells (HEK293)

Synonyms: VEGFC, Flt4-L, VRP, Vascular endothelial growth factor-related proteinVascular endothelial growth factor CFlt4 ligand

More details

VEC-H4225-1K

Availability: within 7 days

1 500,00 €

Background: Vascular endothelial growth factor C is also known as VEGFC, Flt4-L and VRP, it contains the C-terminal propeptide which has an unusual structure with tandemly repeated cysteine-rich motifs. Upon biosynthesis, VEGFC is secreted as a non-covalent momodimer in an anti-parellel fashion. VEGFC is a member of the platelet-derived growth factor/vascular endothelial growth factor (PDGF/VEGF) family, is active in angiogenesis, lymphangiogenesis and endothelial cell growth and survival, and can also affect the permeability of blood vessels. This secreted protein undergoes a complex proteolytic maturation, generating multiple processed forms that bind and activate VEGFR-3 receptors. Only the fully processed form can bind and activate VEGFR-2 receptors. The structure and function of this protein is similar to those of vascular endothelial growth factor D (VEGF-D). VEGFC may function in angiogenesis of the venous and lymphatic vascular systems during embryogenesis, and also in the maintenance of differentiated lymphatic endothelium in adults. Overexpression of VEGF-C causes lymphatics to enlarge possibly facilitates metastasis.

Source
Recombinant Human VEGF-C /FLT4L Protein (rhVEGF-C) Thr 103 - Arg 227 (Accession # AAH35212.1) was produced in human 293 cells (HEK293).

Molecular Characterization
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 15.0 kDa. The protein migrates as 19-25 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Endotoxin
Less than 1.0 EU per μg of the rhVEGF-C by the LAL method.

Purity
>95% as determined by SDS-PAGE.

Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally Mannitol or Trehalose are added as protectants before lyophilization. 

Reconstitution
See Certificate of Analysis for details of reconstitution instruction and specific concentration.

Storage
Avoid repeated freeze-thaw cycles.
No activity loss was observed after storage at:
In lyophilized state for 1 year (4°C-8°C); After reconstitution under sterile conditions for 1 month (4°C-8°C) or 3 months (-20°C to -70°C).

Bioactivity
Immobilized Human VEGF R3, Fc Tag (Cat. No. FL4-H5251) at 5 μg/mL (100 μL/well) can bind Human VEGF-C, His Tag (Cat. No. VEC-H4225) with a linear range of 2-20 ng/mL (QC tested).
Immobilized Human VEGF-C, His Tag (Cat. No. VEC-H4225) at 2 μg/mL (100 μL/well) can bind Biotinylated Human VEGF R1, His Tag, Avi Tag (Cat. No. VE1-H82E3) with a linear range of 0.02-0.625 μg/mL (Routinely tested).

References
(1) Orpana A, Salven P , 2003, Leuk. Lymphoma 43 (2): 219–24.
(2) Joukov V, et al., 1996, EMBO J., 15(2): 290-98.

The following products could also be interesting for you: